The British/Belgian Gall Stone Study Group (BBGSG) post-dissolution trial was a prospective, multicentre, randomised, double blind trial of: (i) low dose ursodeoxycholic acid, (ii) placebo, and (iii) a high fibre, low refined carbohydrate diet in the prevention of gall stone recurrence in patients with complete gail stone dissolution. Further aims included establishing the timing and frequency of recurrence and its association with biliary symptoms, a comparison of the sensitivity of ultrasonography v oral cholecystectography in detecting recurrent stones, and a search for risk factors predicting recurrence. Ninety three patients entered the study, and 82 were followed up for up to five years (mean (SEM) 28 (1-5) months) with six monthly ultrasonography and yearly oral cholecystectography. There were 21 recurrences (26 by oral cholecystectography or ultrasonography, or both), only two of which were symptomatic, which were detected between 12 and 42 months after trial entry. This corresponded to an actuarial recurrence rate of 33*9 (7.0%) by lifetable analysis at 42 months and subsequently. There were four recurrences in the ursodeoxycholic acid, six in the placebo, and 11 in the diet groups, corresponding to 21*9 (9.9)%, 27-4 (10.1)%, and 45*8 (12-4)% respectively at 42 months by lifetable analysis (NS). Variables including age, obesity, menopausal state, pregnancy, and oestrogen containing drugs were not shown to affect recurrence rate. Men had more frequent recurrence than women (NS). Patients who had had multiple stones experienced more recurrences than did those with single stones (NS). Recurrence did not occur in patients who took non-steroidal anti-inflammatory drugs (NSAIDs) (p<0.02). The stone free interval between stone dissolution and trial entry proved to be important -those stone free>nine months had a recurrence rate of only 12.7 (6.0)% at 42 months compared with 55*4 (12-5)% in those stone free<nine months (p<001). There was imbalance between the ursodeoxycholic acid and placebo groups for this factor, and after applying a statistical correction, the adjusted recurrence rate in the ursodeoxycholic acid group was 15% compared with 30% in both placebo and diet groups (NS). These data suggest that after medical dissolution, the risk of gall stone recurrence is not reduced by a high fibre, low refined carbohydrate diet: it may be lowered, but not abolished, by low dose ursodeoxycholic acid.
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(Gut 1993; 34: 1277-1288) When gall stones have been dissolved and oral bile acid treatment is withdrawn, bile reverts to being supersaturated with cholesterol over one to four weeks'13 and in some patients, gall stones recur. Initial reports suggested that stones recurred in 30-50% of patients within two to five Body weight/obesity - Table I gives the results for initial body weight, expressed both as a percentage of ideal body weight (%IBW) and as the body mass index (BMI:wt/h2). Based on an arbitrary definition of obesity as > 130%IBW, 25 patients were obese and 68 non-obese. Similarly ifobesity is defined, again arbitrarily, as a BMI of >25 in women and >26 in men, there were 32 obese (a number which includes all 25 with %IBW values >130) and 61 non-obese. Large changes in body weight (increases or decreases equal to or >10% of starting weight) were also considered as a possible risk factor. Such changes were seen in 12 patients (six of whom gained and six of whom lost equal to or > 10% of their pre-trial weight).
Previous bile acid treatment and gall stone characteristics -Most (n=62) of the patients had previously taken chenodeoxycholic acid for dissolution of their original or 'primary' gall stones but 27 had taken ursodeoxycholic acid and four had taken a combination of chenodeoxycholic acid and ursodeoxycholic acid. After complete gall stone dissolution, most (n=77) of the patients had taken no post-dissolution treatment but 16 had been given maintenance treatment with half the full dissolution doses of either chenodeoxycholic acid or ursodeoxycholic acid. Six patients who had had gall stone recurrence in the past, followed by successful re-dissolution, were included in the trial. Before primary gall stone dissolution, 16 Patients who fulfilled the inclusion criteria were randomised, from a central office, to one of the three groups (see above) with stratification and secondary 'biased randomisation' for obesity and the stone free interval, as follows:
Obesity -Obesity is a risk factor for primary gall stone formation'"'6 and, therefore, possibly also for the development of recurrent stones. Furthermore, the results of most studies suggest that obese individuals respond less well to oral bile acid treatment than the non-obese. 17-'9 For these reasons, the patients were stratified (as described above) into obese (arbitrarily >130%IBW) and non-obese (<130%IBW) subgroups, using Metropolitan Life Insurance tables. This ensured that after randomisation, there were about equal numbers of obese patients in the three treatment groups (diet, n=5; ursodeoxycholic acid, n=8; placebo, n=9).
Stone free interval -Earlier reports suggested that if gall stones were going to recur, most would do so within two years of stopping bile acid treatment or not at all." Therefore, we reasoned that patients who had been stone free for two years or more might represent a 'protected' subgroup at low risk for recurrence. For this reason, the patients were also stratified according to stone free intervals of >, or <, two years and biased randomisation performed as described above.
FOLLOW UP PROTOCOL
The patients were seen every three months at their local hospital jointly by their own physician and the trial coordinator. At Patients randomised to the tablet groups were advised to continue their pre-trial diets -unless they had already been taking a high fibre diet -in which case they were encouraged to reduce their fibre intake during the trial. Those in the diet group were asked both to reduce their intake of refined carbohydrates and to increase their dietary fibre by substituting high for low fibre products and by taking supplements of standardised wheat bran (three or four x 7-5 g sachets of Prewett's coarse wheat bran). In addition, the patients in the diet group were given dietary advice, printed information sheets, and suggested recipes for high fibre, low refined carbohydrate meals. Table II shows the results of analysing the standardised wheat bran in two separate laboratories. To avoid variation in bran composition over the period of the study, a large supply, adequate for the whole study, was stored centrally and distributed to the patients as necessary.
ETHICAL CONSIDERATIONS
In each of the participating hospitals, Ethical Committee permission was obtained for the study and all patients gave their informed 12 patients. Thus in four the serum cholesterol ranged from 8-9 to 9-7 mmol/l (normal <8-5); in five the serum triglyceride concentrations were raised at 2-4-3-6 mmol/l (normal <2-2) while in three there was mixed hyperlipidaemia. In these and the remaining 70 patients, the serum lipids remained unchanged throughout the study. There was no hypertransaminasaemia either before or during the trial. One patient, who had radiological evidence of Paget's disease of bone, had consistently raised serum alkaline phosphatase concentrations (600-905 U/1: n<300).
COMPLIANCE WITH DIET Figure 1 shows the results for the fibre (A) and sugar (B) scores.
The mean pre-trial fibre scores (approximately 20 points) were almost identical in all three groups. (These scores may be somewhat higher than normal as, before joining the study, some patients had already been encouraged to take a high fibre intake.) During the trial, the mean fibre score in the diet group rose to 12 and 42 months after trial entry corresponding, by LTA, to 0% at six months, 0 6 12 18 24 30 36 8-9 (3 2)% at 12 months, 14-3 (4 0)% at 18 months, 22-9 (4-9)% at 24 months, 29-2 (5 7)% at 36 months, and 33-9 (7 0)% at 42 and subse-J quent months (Fig 2) . (5 0)% at 24 months, 36-4 (6 2)% at 36 months, and 41-0 (7-2)% at 42 and subsequent months.
ps, the mean fibre scores both dropComparative sensitivity ofdifferent imaging techat six months -to 17-9 (212) in the niques in detecting gall stone recurrence -Ultraholic acid treated, and to (1 -3) in sound detected gall stone recurrence earlier and btreated groups -probably because, more frequently than did either the trial criteria poses of the trial, the patients were or oral cholecystectography alone (Fig 3) . Thus, to avoid high fibre foods. There-at six months, no recurrences were detected by ,ever, the fibre scores remained oral cholecystectography, but five were apparent )nstant.
by ultrasonography. All five were confirmed int of entry into the study, the mean subsequently by oral cholecystectography and s were comparable in the ursodeoxy-repeat ultrasonography. By one year, 12 recurcholic acid (8 4 (1 3) points) and diet (8'6 (1 1)) groups but, largely because three obese individuals in the placebo group consistently took large amounts of refined carbohydrates, the mean score in this group was (1 9) . During the trial, the sugar scores remained constant in both tablet groups but, as intended, the scores in the diet group fell by an average of 40-48% . In all three groups, however, the mean values remained constant throughout the study -again implying good compliance in controlling sugar, as well as fibre, intake. With regard to the possibility that large changes in body weight (equal to or >10% of initial weight) might represent a risk factor, only one case of gall stone recurrence was detected in those who lost > 10% of starting weight and none was seen in those who gained weight.
Effect ofpregnancy and oestrogen based treatment There was no significant difference in actuarial recurrence rates at 42 and subsequent months, for pre-menopausal (24-6 (10-9)%) and postmenopausal (35 9 (13-1)%) women (Table III) Stonefree interval (Fig 5) In those who, at the point of entry into the trial, had already been stone free for > the nine month median, there was a significantly lower recurrence rate (12-7 (6 0)% at 42 months by LTA) than in those who had been stone free for <nine months (55 4 (12-5)%; p<0-01). Despite the study design and our attempts to stratify for the stone free interval (based on > or <2 years), there was an imbalance between the three treatment groups on either side of the median (nine months). Although the distribution of patients who were stone free for > or <nine months was about equal in the diet group (43% >nine months and 57% <nine months), it was appreciably different in the two tablet groups. At trial entry, 19 of 28 patients (68%) in the placebo group had already been stone free for equal to or >nine months -compared with only eight of 23 (35%) in the ursodeoxycholic acid group. As the stone free interval proved to be one of the most important predictive factors for gall stone recurrence, this imbalance introduced a potential bias towards a greater recurrence rate in the ursodeoxycholic acid group, than in the placebo group. After correcting for this imbalance by the direct standardisation method,34 the recurrence rate in the ursodeoxycholic acid treated patients (15%) was only half that seen in the other two groups (30%) although this difference still failed to reach statistical significance.
Discussion

PATHOGENESIS OF RECURRENT GALL BLADDER
STONES
Before primary gall stones form, there must be at least a triple3334 defect: (i) the secretion of bile that is supersaturated with cholesterol, (ii) a nucleation defect due to an excess of promotors or a deficiency of inhibitors of crystallisation, or both, and (iii) stasis within the gall bladder secondary to impaired gall bladder motor function.
The same triple defect probably contributes to the formation of recurrent gall bladder stones. Thus, recurrence of supersaturated bile is almost invariable after withdrawing oral bile acid treatment. The defect in gall bladder contractile function also persists after gall stone clearance by oral bile acids alone,3.36 or by extracorporeal shock wave lithotripsy plus adjuvant bile acids.37 It is not known, however, if the nucleation defect also persists after the stones have been removed. Conventionally, cholesterol crystal nucleation times are measured in gall bladder bile obtained by needle aspiration at the time of surgery: they cannot be measured reliably in bile rich duodenal fluid.38 As access to the gall bladder is rarely possible after gall stone clearance, it seemed that, until recently, they could not be studied in patients with complete gall stone dissolution. Swobodnik Duration offollow up After the present study was designed, longterm studies using actuarial analysis were published,7 4253-55 which showed that a longer follow up period than two years was required to establish reliable recurrence data. For this reason, and also to ensure that adequate numbers of patients had been recruited, the present trial was extended from two, to a maximum of five, years. In the event, we never saw gall stone recurrence beyond 3*5 years with the result that there was a plateau in the actuarial recurrence rate after this time. Similar observations have been made by others42 4'55 although in the different studies, the time of onset of the plateau has varied from three to seven years. In all such studies, however (including this trial), the number of patients at risk diminishes appreciably with time so that the confidence of the prediction that there really is a plateau, also diminishes with time.
The stonefree interval The present and other4l 52 54 55 As the results in Figure 5 show, before correcting for the imbalance in the distribution of low risk patients (stone free >nine months) between the three groups, there was no significant difference in the actuarial recurrence rates between the ursodeoxycholic acid and diet groups -despite a twofold difference in mean values. The absence of a significant difference in LTA recurrence rates, however, may represent a type II error due to inadequate numbers towards the end of the study, rather than to a lack of effect. Frequency ofgall stone recurrence In this study, the highest figure for gall stone recurrence is 26 (diagnosed by either oral cholecystectography or ultrasonography) of 82 patients followed up for at least six months (60 of whom were followed up for not less than two years) giving a crude recurrence rate of 31-7% which corresponds, by LTA, to a cumulative actuarial rate of 41-0 (7 2)% at 3 5 and subsequent years. These overall results may be distorted, however, by the influence of postdissolution treatment. Therefore, they may not be representative ofrecurrence rates in untreated individuals.
Although gall stone recurrence rates of 30-40% are substantial, they are, none the less, considerably less than those reported in many other studies.42485455 One reason for these variable results may relate to the differing degrees of stringency applied to the diagnosis and confirmation of complete gall stone dissolution.
The present studies are important not only for gall stone recurrence after oral dissolution treatment but also for recurrence in any situation where the gall bladder remains in situ but the stones have been removed by percutaneous cholecystolithotomy, instillation of contact solvents such as methyl ter-butyl ether and, to a lesser extent because of patient selection, by extra corporeal shock wave lithotripsy with or without adjuvant bile acids. Based on these findings, and on those by Villanova et The assumption that once a gall stone inducing risk factor is present it will persist, may not always apply. Thus, the primary stones may have developed in women during the childbearing period of life as a result of the cyclic production of hormones, pregnancy or the ingestion ofoestrogen containing oral contraceptive drugs, or both.'--" Transfer of these subjects from premenopausal to postmenopausal 'status' should, theoretically, reduce the risk of developing recurrent stones. Conversely, the prescription of hormone replacement treatment as prophylaxis against postmenopausal oesteoporosis, could diminish this potential benefit. In this study, there were too few patients who became menopausal during the study for valid analyses. More longterm studies would be necessary to answer this point. Furthermore, patients who were obese, or actively loosing weight at the time when the primary gall stones developed might, on achieving ideal body weight, no longer suffer this risk factor. Again there are too few patients who fall into the category of significant changes in body weight to permit valid conclusions but given the limited information, this did not seem to influence these results.
